




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : C07D 239/02, 217/12, 411/00, 211/80, 277/18, A61K 31/505, 31/47, 31/44, 31/425	A1	(11) International Publication Number: WO 99/15508 (43) International Publication Date: 1 April 1999 (01.04.99)
(21) International Application Number: PCT/US98/19466 (22) International Filing Date: 18 September 1998 (18.09.98) (30) Priority Data: 60/059,342 19 September 1997 (19.09.97) US 60/063,438 29 October 1997 (29.10.97) US (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19103 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BONDINELL, William, E. [US/US]; 1512 Franklin Lane, Wayne, PA 19087 (US). MILLER, William, H. [US/US]; 333 Fell Lane, Schwenksville, PA 19473 (US). HEERDING, Dirk [NL/US]; 1 Mill Creek Lane, Malvern, PA 19355 (US). SAMANEN, James, Martin [US/US]; 145 Jug Hollow Road, Phoenixville, PA 19460 (US). (74) Agents: MCCARTHY, Mary, E. et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.

(54) Title: VITRONECTIN RECEPTOR ANTAGONISTS



(57) Abstract

Compounds of formula (I) are disclosed which are vitronectin receptor antagonists and are useful in the treatment of osteoporosis wherein: A is CH₂ or O; R¹ is H, halo or C₁₋₆alkyl; R² is H, C₁₋₆alkyl or CH₂NR''R'''; X is O or CH₂; Y is (a), (b), (c), (d), (e), (f) or (g); G is NR'', S or O; R' is H, C₁₋₆alkyl, OC₁₋₆alkyl, SC₁₋₆alkyl, NR''R'' or halo; each R'' independently is H or C₁₋₆alkyl; and s is 0, 1 or 2; or a pharmaceutically acceptable salt thereof.